Halozyme Therapeutics revenue and financials
$109.72Change from previous close: +1.30%Absolute change: +$1.41
In the fiscal year ended December 2025, Halozyme Therapeutics reported revenue of $1.4B (+37.55% year over year). Net income was $316.89M, a net margin of 22.7%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +37.55%
- 2025 vs 2024
- Net income growth
- −28.64%
- 2025 vs 2024
- Net margin
- 22.7%
- 2024: 43.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2,525 | 2,063 | 1,733 | 1,842 | 1,104 | 580 | 566 | 440 | 520 | 262 |
| Current assets | 825 | 1,085 | 746 | 739 | 926 | 555 | 543 | 428 | 510 | 257 |
| Cash and equivalents | 134 | 116 | 118 | 234 | 119 | 148 | 120 | 57.9 | 169 | 66.8 |
| Short-term investments | 9.0 | 480 | 218 | 129 | 622 | — | — | — | — | — |
| Receivables | 441 | 308 | 234 | 231 | 91.0 | — | — | — | — | — |
| Inventory | 176 | 142 | 128 | 100 | 53.9 | — | — | — | — | — |
| Net property, plant and equipment | 82.1 | 75.0 | 74.9 | 75.6 | 8.8 | — | — | — | — | — |
| Goodwill | 580 | 417 | 417 | 409 | — | — | — | — | — | — |
| Other intangible assets | 981 | 402 | 473 | 547 | — | — | — | — | — | — |
| Current liabilities | 177 | 139 | 112 | 131 | 117 | 421 | 85.6 | 149 | 131 | 54.6 |
| Accounts payable | 20.9 | 10.2 | 11.8 | 17.7 | 1.5 | — | — | — | — | — |
| Long-term debt | 2,143 | 1,506 | 1,499 | 1,493 | 787 | 0.0 | 383 | 34.9 | 125 | 199 |
| Total debt | 2,143 | 1,506 | 1,499 | 1,506 | — | — | — | — | — | — |
| Total liabilities | 2,477 | 1,700 | 1,649 | 1,672 | 907 | — | — | — | — | — |
| Total equity (incl. minority) | 48.8 | 364 | 83.8 | 170 | 197 | — | — | — | — | — |
| Retained earnings | 54.8 | 360 | 90.6 | 143 | -58.9 | — | — | — | — | — |